Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHOP with or without bortezomib for relapsed mantle cell lymphoma
ISRCTN20159589Phase 2Completed
- Sponsor
- University Hospitals Plymouth
- Start
- Jun 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 2, randomised, open-label trial of bortezomib, cyclophosphamide, doxorubicin, vincristine and prednisolone in mantle cell lymphoma (MCL) (2 arms), sponsored by University Hospitals Plymouth. Primary endpoints: Complete response and Partial response. Started Jun 2007; status: completed.
02
Drugs
bortezomibcyclophosphamidedoxorubicinvincristineprednisolone
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on ISRCTN20159589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN20159589.